Howard A. Burris, MD, Talks QOL With Durvalumab/Chemo in Advanced Biliary Tract Cancer From TOPAZ-1 Trial


Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes data that were presented at 2022 ASCO.

In an interview with CancerNetwork® during the 2022 American Society of Clinical Oncology Annual Meeting, Howard A. Burris, MD, president and chief medical officer of Sarah Cannon as well as an associate of Tennessee Oncology, discussed the safety profile as well as patient-reported outcomes from the phase 3 TOPAZ-1 trial (NCT03875235) of gemcitabine and cisplatin plus either durvalumab (Imfinzi) or placebo in advanced biliary tract cancer (BTC).1

In addition to improved overall survival (OS) and progression-free survival (PFS), the active therapy arm was well tolerated and yielded no difference in time to deterioration of quality-of-life, which further supports the use of the regimen in patients with BTC.


TOPAZ-1 was a clinical trial studying the addition of durvalumab, the PD-1 inhibitor, to the standard chemotherapy regimen of gemcitabine and cisplatin in the treatment of unresectable cholangiocarcinoma or biliary [tract cancer]. In that clinical trial, we showed a statistically significant improvement in overall survival.2

In addition to statistically significant outcomes, one of the factors we look at [is whether] we have a positive effect on quality of life and the [patient’s] ability to handle the regimen with the adverse effects, or toxicity profile. Interestingly, the most impressive survival differences, an objective outcome, was the fact that at 2 years, 25% of patients were alive in the arm that received durvalumab with chemotherapy vs 10% in the group of patients who received chemotherapy alone. After the initial 8 cycles of chemotherapy—patients, in general, tend to receive 6 to 8 cycles—patients received maintenance durvalumab or maintenance placebo. That duration of survival difference points in the direction that patients were able to tolerate the regimen and able to stay on study.


  1. Burris HA, Okusaka T, Vogel A, et al. Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. J Clin Oncol. 2022;40(suppl 16):4070-4070. doi:10.1200/JCO.2022.40.16_suppl.4070
  2. Oh DY, He AR, Qin S, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J Clin Oncol. 2022;40(suppl 4):378. doi:10.1200/JCO.2022.40.4_suppl.378
Related Videos
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.